Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 625 - 632 of 12007 results
FCA Settlements Demonstrate Importance of Cybersecurity Controls Imposed by Contract
August 20, 2024| News
Tech Funding, IPOs Are Less Frequent in 2024
August 20, 2024| News
2024 Pre-Election Analysis: Tax Issues
August 19, 2024| Advisory| Viewpoint
Federal Court in Florida Issues Another Limited Preliminary Injunction Against the FTC’s Non-Compete Rule
August 19, 2024| Blog| Viewpoint
CMS Issues Final Notice on Program for Breakthrough Device Reimbursement but Industry Looks to Congress for More Inclusive Solution
August 19, 2024| Blog| Viewpoint
AI Is Ushering in a Tech Lawyer 'Golden Age'
August 18, 2024| News
Medicare Drug Price Cuts Add Fuel to Legal Fight Over Program
August 16, 2024| News
DOJ Issues its Highly Anticipated Whistleblower Awards Pilot Program
August 15, 2024| Blog| Viewpoint
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|
Health Law Diagnosed: PBM Update Spring 2025
June 10, 2025| Podcast|